VENLAFAXINE
Generic: VENLAFAXINE, VENLAFAXINE HYDROCHLORIDE
BluePoint LaboratoriesManufacturer
ORALRoute
VENLAFAXINE HYDROCHLORIDEActive Substance
2008-06-13Original Approval
VENLAFAXINE is FDA application ANDA077653, sponsored by ZYDUS PHARMS USA. Any recalls listed below come from FDA drug enforcement reports, and reaction counts are the number of FAERS adverse event reports that mention the drug and that reaction; a report does not prove the drug caused it.
Recalls
Class II2016-07-19
Venlafaxine HCL ER Capsule USP, 150mg, packaged in a) 30-count bottles (NDC 68382-036-06), b) 90-count bottles (NDC 6838Failed Dissolution Specifications: out of specification dissolution results in retained samples
Class II2016-12-22
Venlafaxine Hydrochloride extended release capsules, 37.5 mg, 30-count bottles, Rx Only, Manufactured for: Aurobindo PhaFailed Tablet/Capsule Specifications: Some bottles contain punctured, and/or clumped/melted capsule
Class II2024-06-21
Venlafaxine Hydrochloride Extended-Release Capsules, USP 37.5mg, packaged in a) 90-count bottles (NDC 68382-034-16) and Failed Dissolution Specifications: Out-of-specification results observed for dissolution testing at
Class II2016-07-19
Venlafaxine HCL ER Capsule USP, 75mg, packaged in a) 30-count bottles (NDC 68382-035-06), b) 90-count bottles (NDC 68382Failed Dissolution Specifications: out of specification dissolution results in retained samples
Top Reported Reactions
1
DRUG INEFFECTIVE
5,934 reports
2
NAUSEA
4,685 reports
3
TOXICITY TO VARIOUS AGENTS
4,577 reports
4
OFF LABEL USE
4,575 reports
5
FATIGUE
4,433 reports
6
HEADACHE
3,971 reports
7
COMPLETED SUICIDE
3,361 reports
8
DRUG INTERACTION
3,354 reports
9
DIZZINESS
3,200 reports
10
DIARRHOEA
2,938 reports